Literature DB >> 18344322

Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia.

Lan Wang1, Guang-Biao Zhou, Ping Liu, Jun-Hong Song, Yang Liang, Xiao-Jing Yan, Fang Xu, Bing-Shun Wang, Jian-Hua Mao, Zhi-Xiang Shen, Sai-Juan Chen, Zhu Chen.   

Abstract

To enhance therapeutic efficacy and reduce adverse effects, practitioners of traditional Chinese medicine (TCM) prescribe a combination of plant species/minerals, called formulae, based on clinical experience. Nearly 100,000 formulae have been recorded, but the working mechanisms of most remain unknown. In trying to address the possible beneficial effects of formulae with current biomedical approaches, we use Realgar-Indigo naturalis formula (RIF), which has been proven to be very effective in treating human acute promyelocytic leukemia (APL) as a model. The main components of RIF are realgar, Indigo naturalis, and Salvia miltiorrhiza, with tetraarsenic tetrasulfide (A), indirubin (I), and tanshinone IIA (T) as major active ingredients, respectively. Here, we report that the ATI combination yields synergy in the treatment of a murine APL model in vivo and in the induction of APL cell differentiation in vitro. ATI causes intensified ubiquitination/degradation of promyelocytic leukemia (PML)-retinoic acid receptor alpha (RARalpha) oncoprotein, stronger reprogramming of myeloid differentiation regulators, and enhanced G(1)/G(0) arrest in APL cells through hitting multiple targets compared with the effects of mono- or biagents. Furthermore, ATI intensifies the expression of Aquaglyceroporin 9 and facilitates the transportation of A into APL cells, which in turn enhances A-mediated PML-RARalpha degradation and therapeutic efficacy. Our data also indicate A as the principal component of the formula, whereas T and I serve as adjuvant ingredients. We therefore suggest that dissecting the mode of action of clinically effective formulae at the molecular, cellular, and organism levels may be a good strategy in exploring the value of traditional medicine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18344322      PMCID: PMC2290784          DOI: 10.1073/pnas.0712365105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  'Back to the future' for Chinese herbal medicines.

Authors:  Jane Qiu
Journal:  Nat Rev Drug Discov       Date:  2007-07       Impact factor: 84.694

2.  Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Eur J Biochem       Date:  1981-03-16

3.  Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.

Authors:  R Hoessel; S Leclerc; J A Endicott; M E Nobel; A Lawrie; P Tunnah; M Leost; E Damiens; D Marie; D Marko; E Niederberger; W Tang; G Eisenbrand; L Meijer
Journal:  Nat Cell Biol       Date:  1999-05       Impact factor: 28.824

Review 4.  Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.

Authors:  M A Shah; G K Schwartz
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

5.  A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities.

Authors:  E Duprez; G Benoit; M Flexor; J R Lillehaug; M Lanotte
Journal:  Leukemia       Date:  2000-02       Impact factor: 11.528

6.  Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene.

Authors:  H de Thé; M M Vivanco-Ruiz; P Tiollais; H Stunnenberg; A Dejean
Journal:  Nature       Date:  1990-01-11       Impact factor: 49.962

Review 7.  Arsenic trioxide, a therapeutic agent for APL.

Authors:  T D Zhang; G Q Chen; Z G Wang; Z Y Wang; S J Chen; Z Chen
Journal:  Oncogene       Date:  2001-10-29       Impact factor: 9.867

Review 8.  How acute promyelocytic leukaemia revived arsenic.

Authors:  Jun Zhu; Zhu Chen; Valérie Lallemand-Breitenbach; Hugues de Thé
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

Review 9.  Cdk2 dethroned as master of S phase entry.

Authors:  Philip W Hinds
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

10.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

Authors:  M E Huang; Y C Ye; S R Chen; J R Chai; J X Lu; L Zhoa; L J Gu; Z Y Wang
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

View more
  221 in total

1.  Combination treatment with dihydrotanshinone I and irradiation enhances apoptotic effects in human cervical cancer by HPV E6 down-regulation and caspases activation.

Authors:  Yintao Ye; Wenqing Xu; Wei Zhong; Yajing Li; Chen Wang
Journal:  Mol Cell Biochem       Date:  2011-12-07       Impact factor: 3.396

2.  Convergence: Where West meets East.

Authors:  Peng Tian
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

3.  Discovery of regularities in the use of herbs in Chinese medicine prescriptions.

Authors:  Tao Chen; Xue-zhong Zhou; Run-shun Zhang; Lian-wen Zhang
Journal:  Chin J Integr Med       Date:  2011-10-12       Impact factor: 1.978

Review 4.  Future perspectives of Chinese medical formulae: chinmedomics as an effector.

Authors:  Xijun Wang; Aihua Zhang; Hui Sun
Journal:  OMICS       Date:  2012-06-26

5.  Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China.

Authors:  Xiao-mei Hu; Feng Liu; Rou Ma
Journal:  Chin J Integr Med       Date:  2010-08-10       Impact factor: 1.978

6.  Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia?

Authors:  Hong-Fang Ji; Xue-Juan Li; Hong-Yu Zhang
Journal:  EMBO Rep       Date:  2009-02-20       Impact factor: 8.807

Review 7.  Current situation and progress in integrative medicine in China.

Authors:  Ai-ping Lu; Xiao-rong Ding; Ke-ji Chen
Journal:  Chin J Integr Med       Date:  2008-10-14       Impact factor: 1.978

8.  Quality control of natural product medicine and nutrient supplements.

Authors:  Shuang-Qing Zhang; Feng Wei; Yu-Ming Fan; Feng Sun; Ying-Yong Zhao; Shuhua Bai
Journal:  J Anal Methods Chem       Date:  2013-07-16       Impact factor: 2.193

9.  Tanshinone IIA and astragaloside IV promote the migration of mesenchymal stem cells by up-regulation of CXCR4.

Authors:  Juan Xie; Huan Wang; Tiebing Song; Zongren Wang; Feng Li; Jing Ma; Jun Chen; Yayun Nan; Hui Yi; Wen Wang
Journal:  Protoplasma       Date:  2012-08-08       Impact factor: 3.356

10.  Retrospective analysis of 119 cases of pediatric acute promyelocytic leukemia: Comparisons of four treatment regimes.

Authors:  En-Qin Li; Ling Xu; Zhi-Quan Zhang; Yan Xiao; Hai-Xia Guo; Xue-Qun Luo; Qun Hu; Dong-Bo Lai; Li-Ming Tu; Run-Ming Jin
Journal:  Exp Ther Med       Date:  2012-04-17       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.